Cytokinetics
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
350 Oyster Point Blvd, South San Francis...Phone Number
(650) 624-3000Website
www.cytokinetics.comRevenue
$105.8 MillionStock Symbol
CYTKIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Founded in South San Francisco, California, by pioneers in the field of muscle biology, we have been leveraging our scientific expertise to develop new medicines for patients.Explore more
Cytokinetics Org Chart
JC
Global Executive Director, Supply Chain
BL
Head Senior Director, Regulatory Labeling
BP
Senior Director, Trade & Distribution
JV
Head Senior Director, Chemical Development & ...
JB
Senior Director, Project Management
CB
Senior Director, Facilities EH & S
KC
Director
IK
Director, Program Management
FG
Director, Operational Excellence
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytokinetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cytokinetics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cytokinetics launches new products
Check out if Cytokinetics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cytokinetics recently announced quarterly report
Check if Cytokinetics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cytokinetics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cytokinetics
Click to see if Cytokinetics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cytokinetics
Compare insights from companies similar to Cytokinetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cytokinetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cytokinetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cytokinetics.
Cytokinetics financials insights
Gather financial insights about Cytokinetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$89.7M
2006
Stock Offering
$33M
2017
Other Financing Round
$100M
Cytokinetics Tech Stack
A closer look at the technologies used by Cytokinetics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Cytokinetics News & Media
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Authorisation from MRHA and Recommendation from NICECytokinetics to Announce Second Quarter Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,220 shares of common stock and 14,067 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June and July 2026 as a material inducement to their employment.What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytokinetics
Sign Up For FreeTo access detailed company insights
Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Founded in South San Francisco, California, by pioneers in... Read More
